MBD2's Role in Silencing SFRP1 Identifies Potential CRC Therapeutic Targets
MBD2 suppresses SFRP1 expression in colorectal cancer by blocking MED19 binding to its methylated promoter.
Asset / Drug
Drug and asset intelligence for MBD2 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.